NCT04706286View on ClinicalTrials.gov

Clinical Trial to Investigate the Pharmacokinetics and Safety of CKD-393

PHASE1UnknownINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

February 18, 2021

Primary Completion Date

March 29, 2021

Study Completion Date

April 5, 2021

Conditions
T2DM (Type 2 Diabetes Mellitus)
Interventions
DRUG

CKD-501, D759, D150

CKD-501 0.5 mg 1T, D759 100 mg 1T and D150 1000 mg 1T, single oral administration under fed condition

DRUG

CKD-393 0.5/100/1000 mg

CKD-393 0.5/100/1000 mg 1T, single oral administration under fed condition

Trial Locations (1)

Unknown

Severance Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Chong Kun Dang Pharmaceutical

INDUSTRY